European Registry on the Management of Helicobacter Pylori Infection View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2013-2024

ABSTRACT

The great diversity of regimens and treatment lines, the different efficacy of these, mostly due to the increase in bacterial antibiotic resistance and regional differences, requires a continuous critical analysis of clinical practice, evaluating systematically the efficacy and safety of the different regimens and the cost-effectiveness of the different diagnostic-therapeutic strategies. This will help in the design of an efficient and optimized treatment that will reduce number of re-treatments, diagnostic tests and the appearance of associated pathologies such as peptic ulcers, gastrointestinal bleeding and, probably, gastric cancers. Therefore, the evaluation of real clinical practice using non-interventionist registries will help to improve the design and organization of European Consensus on the management of H. pylori infection, which is the best way to establish healthcare efficiency. Primary aim To obtain a database registering systematically over a year a large and representative sample of routine clinical practice of European gastroenterologists in order to produce descriptive studies of the management of H. pylori infection. Secondary aims 1. To evaluate H. pylori infection consensus and clinical guidelines implementation in different countries. 2. To perform studies focused on epidemiology, efficacy and safety of the commonly used treatments to eradicate H. pylori. 3. To evaluate accessibility to healthcare technologies and drugs used in the management of H. pylori infection. 4. To allow the development of partial and specific analysis by the participating researchers after approval by the Registry's Scientific Committee Methodology Non-interventionist prospective multicentre international registry promoted by the European Helicobacter Study Group. A renowned gastroenterologist from each country was selected as Local Coordinator (30 countries). They will in turn select up to ten gastroenterologists per country that will register the routine clinical practice consultations they receive over 10 years in an electronic Case Report Form (e-CRF). Variables retrieved will include clinical, diagnostic, treatment, eradication confirmation and outcome data. The database will allow researchers to perform specific subanalysis after approval by the Scientific Committee of the study. Detailed Description Abstract Introduction: H. pylori selectively infects the human stomach mucosa, being the most prevalent chronic infection in the world. Its prevalence correlates with socioeconomic factors and it is higher in older individuals. H. pylori presence causes chronic gastritis in 100% of infected patients and is the major cause of relevant diseases such as atrophic gastritis, peptic ulcer disease and gastric cancer; it is for this reason that from a public health standpoint it is considered a high impact pathogen, responsible of a significant morbidity and mortality. Nowadays there are Consensus and Clinical Guidelines regarding the infection management at a European level and in most of the states, but no data have shown the level of implementation of these recommendations. The high costs that this infection carries both socially and to the health system require the continuous and systematic assessment of the diagnostic and treatment strategies, as well as the accessibility to diagnostic methods and most efficient drugs. Aim: To register the treatment, diagnosis and management strategies of H. pylori infected adult patients in the Digestive Services outpatient clinics throughout Europe. Methods: Non-interventionist prospective multicentre international registry promoted by the European Helicobacter Study Group. A renowned gastroenterologist from each country was selected as Local Coordinator (30 countries). They will in turn select up to ten gastroenterologists per country that will register the routine clinical practice consultations they receive over 10 years in an electronic Case Report Form (e-CRF). Variables retrieved will include clinical, diagnostic, treatment, eradication confirmation and outcome data. The database will allow researchers to perform specific subanalysis after approval by the Scientific Committee of the study. INTRODUCTION H. pylori presence causes chronic gastritis in 100% of infected patients and is the major cause of relevant diseases such as atrophic gastritis, peptic ulcer disease and gastric cancer. H. pylori eradication prevents peptic ulcer recurrence and its complications, and decreases the incidence of gastric cancer. H. pylori eradication in patients with peptic ulcer or even functional or non-investigated dyspepsia is a cost-effective strategy. The most common clinical manifestation of H. pylori infection is dyspepsia, a major health problem, whose prevalence reaches more than 10% among adult populations with its attendant burden of morbidity and health system costs in diagnosis and treatment. Approximately 20% to 30% of people in the community each year report chronic or recurrent dyspeptic symptoms, and consultations for dyspepsia account for up to 40% of referrals among gastroenterology outpatients, the "test-and-treat" strategy being the most cost-effective. Moreover, H. pylori is the major cause of peptic ulcer disease, causing over 90% of duodenal and 70% of gastric ulcers. Considerable evidence supports that the nature of the chronic inflammatory process driven by H. pylori is of critical importance in gastric carcinogenesis (adenocarcinoma and mucosa-associated lymphoid tissue -MALT- lymphoma). It is for that reason that the WHO's International Agency for Research on Cancer classified H. pylori as a group 1 (definite) carcinogen. Scientific evidence demonstrates that diagnosis and eradication of H. pylori is the most cost-effective strategy in the management of dyspepsia, peptic ulcer and gastric cancer prevention. The treatment regimens are very diverse and have changed overtime. Monotherapies and treatments with two drugs did not achieve acceptable eradication rates. The commonly recommended regimen in most Consensus Conferences is the standard triple regimen, combining two antibiotics (clarithromycin with amoxicillin or metronidazole) and a proton pump inhibitor (PPI) for 7 to 14 days. Another recommended alternative is bismuth-containing quadruple therapy (PPI, tetracycline, metronidazole and bismuth salts). In the last years, results with new and efficient rescue regimens including levofloxacin have been published. Lately, new treatments have been proposed, including non-bismuth quadruple regimens, with two main variants: the "sequential" treatment (an induction phase with PPI and amoxicillin and a second phase with PPI, clarithromycin and metronidazole) and the "concomitant" treatment (same four drugs taken altogether). The great diversity of regimens and treatment lines, the different efficacy of these, mostly due to the increase in bacterial antibiotic resistance and regional differences, requires a continuous critical analysis of clinical practice, evaluating systematically the efficacy and safety of the different regimens and the cost-effectiveness of the different diagnostic-therapeutic strategies. This will help in the design of an efficient and optimized treatment that will reduce number of re-treatments, diagnostic tests and the appearance of associated pathologies such as peptic ulcers, gastrointestinal bleeding and, probably, gastric cancers. Therefore, the evaluation of real clinical practice using non-interventionist registries will help to improve the design and organization of European Consensus on the management of H. pylori infection, which is the best way to establish healthcare efficiency. AIMS Primary aim To obtain a database registering systematically over a year a large and representative sample of routine clinical practice of European gastroenterologists in order to produce descriptive studies of the management of H. pylori infection. Secondary aims 1. To evaluate H. pylori infection consensus and clinical guidelines implementation in different countries. 2. To perform studies focused on epidemiology, efficacy and safety of the commonly used treatments to eradicate H. pylori. 3. To evaluate accessibility to healthcare technologies and drugs used in the management of H. pylori infection. 4. To allow the development of partial and specific analysis by the participating researchers after approval by the Registry's Scientific Committee. METHODS International multicenter prospective non-interventionist registry promoted by the European Helicobacter Study Group. Scientific Committee - Javier P. Gisbert (President) - Francis Megraud - Colm O'Morain - Adrian G. McNicholl Local Coordinators A list of European Countries has been selected. Included countries were those having at least ten clinical research publications in PubMed regarding H. pylori infection. In each country a Local Coordinator was selected based on its clinical and research activity (Table I). The Local Coordinators will constitute the monitoring and drafting committee of the registry. The Local Coordinators will be in charge of selecting up to 10 recruiting investigators in each country and will be in charge of the follow up and quality of the recruiting; they will be the link between promoters and recruiting investigators. Recruiter Investigators The Recruiting Investigators must be gastroenterologists attending an adult population with a gastroenterology outpatient clinic that assists H. pylori infected patients. Before acceptance the outpatient clinic must attend, in a clinical routine basis, patients in which H. pylori diagnosis or treatment is indicated. Eradication confirmation tests have to be performed routinely. They will register the study variables of their own routine clinical practice in an e-CRF. Study Variables Anonymised Patient Identifiers - Country/Centre/Investigator - Autonumeric Patient identifier number - Gender - Date of Birth - Ethnic Background History and Comorbidity - Drug allergies - Relevant comorbidities - Current concomitant medication Data on Infection - Indication for diagnosis and treatment - Upper Gastrointestinal tract symptoms - Diagnostic Test for current treatment - Number and type of previous eradication attempts Prescribed Treatment - Drugs - Dosage and intakes per day - Length of treatment Compliance - Adherence to treatment (yes/no >90%) Adverse Events - Type of event, intensity, duration and relation with treatment - Treatment withdrawal due to adverse events. Efficacy - Eradication (yes/no), test used, and date More... »

URL

https://clinicaltrials.gov/show/NCT02328131

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3177", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3114", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The great diversity of regimens and treatment lines, the different efficacy of these, mostly due to the increase in bacterial antibiotic resistance and regional differences, requires a continuous critical analysis of clinical practice, evaluating systematically the efficacy and safety of the different regimens and the cost-effectiveness of the different diagnostic-therapeutic strategies. This will help in the design of an efficient and optimized treatment that will reduce number of re-treatments, diagnostic tests and the appearance of associated pathologies such as peptic ulcers, gastrointestinal bleeding and, probably, gastric cancers. Therefore, the evaluation of real clinical practice using non-interventionist registries will help to improve the design and organization of European Consensus on the management of H. pylori infection, which is the best way to establish healthcare efficiency. Primary aim To obtain a database registering systematically over a year a large and representative sample of routine clinical practice of European gastroenterologists in order to produce descriptive studies of the management of H. pylori infection. Secondary aims 1. To evaluate H. pylori infection consensus and clinical guidelines implementation in different countries. 2. To perform studies focused on epidemiology, efficacy and safety of the commonly used treatments to eradicate H. pylori. 3. To evaluate accessibility to healthcare technologies and drugs used in the management of H. pylori infection. 4. To allow the development of partial and specific analysis by the participating researchers after approval by the Registry's Scientific Committee Methodology Non-interventionist prospective multicentre international registry promoted by the European Helicobacter Study Group. A renowned gastroenterologist from each country was selected as Local Coordinator (30 countries). They will in turn select up to ten gastroenterologists per country that will register the routine clinical practice consultations they receive over 10 years in an electronic Case Report Form (e-CRF). Variables retrieved will include clinical, diagnostic, treatment, eradication confirmation and outcome data. The database will allow researchers to perform specific subanalysis after approval by the Scientific Committee of the study.\n\nDetailed Description\nAbstract Introduction: H. pylori selectively infects the human stomach mucosa, being the most prevalent chronic infection in the world. Its prevalence correlates with socioeconomic factors and it is higher in older individuals. H. pylori presence causes chronic gastritis in 100% of infected patients and is the major cause of relevant diseases such as atrophic gastritis, peptic ulcer disease and gastric cancer; it is for this reason that from a public health standpoint it is considered a high impact pathogen, responsible of a significant morbidity and mortality. Nowadays there are Consensus and Clinical Guidelines regarding the infection management at a European level and in most of the states, but no data have shown the level of implementation of these recommendations. The high costs that this infection carries both socially and to the health system require the continuous and systematic assessment of the diagnostic and treatment strategies, as well as the accessibility to diagnostic methods and most efficient drugs. Aim: To register the treatment, diagnosis and management strategies of H. pylori infected adult patients in the Digestive Services outpatient clinics throughout Europe. Methods: Non-interventionist prospective multicentre international registry promoted by the European Helicobacter Study Group. A renowned gastroenterologist from each country was selected as Local Coordinator (30 countries). They will in turn select up to ten gastroenterologists per country that will register the routine clinical practice consultations they receive over 10 years in an electronic Case Report Form (e-CRF). Variables retrieved will include clinical, diagnostic, treatment, eradication confirmation and outcome data. The database will allow researchers to perform specific subanalysis after approval by the Scientific Committee of the study. INTRODUCTION H. pylori presence causes chronic gastritis in 100% of infected patients and is the major cause of relevant diseases such as atrophic gastritis, peptic ulcer disease and gastric cancer. H. pylori eradication prevents peptic ulcer recurrence and its complications, and decreases the incidence of gastric cancer. H. pylori eradication in patients with peptic ulcer or even functional or non-investigated dyspepsia is a cost-effective strategy. The most common clinical manifestation of H. pylori infection is dyspepsia, a major health problem, whose prevalence reaches more than 10% among adult populations with its attendant burden of morbidity and health system costs in diagnosis and treatment. Approximately 20% to 30% of people in the community each year report chronic or recurrent dyspeptic symptoms, and consultations for dyspepsia account for up to 40% of referrals among gastroenterology outpatients, the \"test-and-treat\" strategy being the most cost-effective. Moreover, H. pylori is the major cause of peptic ulcer disease, causing over 90% of duodenal and 70% of gastric ulcers. Considerable evidence supports that the nature of the chronic inflammatory process driven by H. pylori is of critical importance in gastric carcinogenesis (adenocarcinoma and mucosa-associated lymphoid tissue -MALT- lymphoma). It is for that reason that the WHO's International Agency for Research on Cancer classified H. pylori as a group 1 (definite) carcinogen. Scientific evidence demonstrates that diagnosis and eradication of H. pylori is the most cost-effective strategy in the management of dyspepsia, peptic ulcer and gastric cancer prevention. The treatment regimens are very diverse and have changed overtime. Monotherapies and treatments with two drugs did not achieve acceptable eradication rates. The commonly recommended regimen in most Consensus Conferences is the standard triple regimen, combining two antibiotics (clarithromycin with amoxicillin or metronidazole) and a proton pump inhibitor (PPI) for 7 to 14 days. Another recommended alternative is bismuth-containing quadruple therapy (PPI, tetracycline, metronidazole and bismuth salts). In the last years, results with new and efficient rescue regimens including levofloxacin have been published. Lately, new treatments have been proposed, including non-bismuth quadruple regimens, with two main variants: the \"sequential\" treatment (an induction phase with PPI and amoxicillin and a second phase with PPI, clarithromycin and metronidazole) and the \"concomitant\" treatment (same four drugs taken altogether). The great diversity of regimens and treatment lines, the different efficacy of these, mostly due to the increase in bacterial antibiotic resistance and regional differences, requires a continuous critical analysis of clinical practice, evaluating systematically the efficacy and safety of the different regimens and the cost-effectiveness of the different diagnostic-therapeutic strategies. This will help in the design of an efficient and optimized treatment that will reduce number of re-treatments, diagnostic tests and the appearance of associated pathologies such as peptic ulcers, gastrointestinal bleeding and, probably, gastric cancers. Therefore, the evaluation of real clinical practice using non-interventionist registries will help to improve the design and organization of European Consensus on the management of H. pylori infection, which is the best way to establish healthcare efficiency. AIMS Primary aim To obtain a database registering systematically over a year a large and representative sample of routine clinical practice of European gastroenterologists in order to produce descriptive studies of the management of H. pylori infection. Secondary aims 1. To evaluate H. pylori infection consensus and clinical guidelines implementation in different countries. 2. To perform studies focused on epidemiology, efficacy and safety of the commonly used treatments to eradicate H. pylori. 3. To evaluate accessibility to healthcare technologies and drugs used in the management of H. pylori infection. 4. To allow the development of partial and specific analysis by the participating researchers after approval by the Registry's Scientific Committee. METHODS International multicenter prospective non-interventionist registry promoted by the European Helicobacter Study Group. Scientific Committee - Javier P. Gisbert (President) - Francis Megraud - Colm O'Morain - Adrian G. McNicholl Local Coordinators A list of European Countries has been selected. Included countries were those having at least ten clinical research publications in PubMed regarding H. pylori infection. In each country a Local Coordinator was selected based on its clinical and research activity (Table I). The Local Coordinators will constitute the monitoring and drafting committee of the registry. The Local Coordinators will be in charge of selecting up to 10 recruiting investigators in each country and will be in charge of the follow up and quality of the recruiting; they will be the link between promoters and recruiting investigators. Recruiter Investigators The Recruiting Investigators must be gastroenterologists attending an adult population with a gastroenterology outpatient clinic that assists H. pylori infected patients. Before acceptance the outpatient clinic must attend, in a clinical routine basis, patients in which H. pylori diagnosis or treatment is indicated. Eradication confirmation tests have to be performed routinely. They will register the study variables of their own routine clinical practice in an e-CRF. Study Variables Anonymised Patient Identifiers - Country/Centre/Investigator - Autonumeric Patient identifier number - Gender - Date of Birth - Ethnic Background History and Comorbidity - Drug allergies - Relevant comorbidities - Current concomitant medication Data on Infection - Indication for diagnosis and treatment - Upper Gastrointestinal tract symptoms - Diagnostic Test for current treatment - Number and type of previous eradication attempts Prescribed Treatment - Drugs - Dosage and intakes per day - Length of treatment Compliance - Adherence to treatment (yes/no >90%) Adverse Events - Type of event, intensity, duration and relation with treatment - Treatment withdrawal due to adverse events. Efficacy - Eradication (yes/no), test used, and date", 
    "endDate": "2024-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT02328131", 
    "keywords": [
      "management", 
      "Helicobacter", 
      "great diversity", 
      "regimen", 
      "different efficacy", 
      "Bacterial Drug Resistance", 
      "regional difference", 
      "critical analysis", 
      "clinical practice", 
      "efficacy", 
      "safety", 
      "different regimen", 
      "cost-effectiveness", 
      "therapeutic strategy", 
      "re", 
      "Routine Diagnostic Test", 
      "appearance", 
      "associated pathology", 
      "peptic ulcer", 
      "Stomach Neoplasm", 
      "Evaluation Study as Topic", 
      "interventionists", 
      "consensus", 
      "H. pylorus infection", 
      "efficiency", 
      "primary aim", 
      "registering", 
      "representative sample", 
      "routine clinical practice", 
      "gastroenterologist", 
      "descriptive study", 
      "guideline implementation", 
      "different country", 
      "epidemiology", 
      "used treatment", 
      "H. pylorus", 
      "accessibility", 
      "healthcare technology", 
      "drug", 
      "development", 
      "specific analysis", 
      "approval", 
      "scientific committee", 
      "International", 
      "study group", 
      "country", 
      "coordinator", 
      "Case Report", 
      "variable", 
      "confirmation", 
      "outcome data", 
      "database", 
      "DESCRIPTION Abstract", 
      "human stomach", 
      "chronic infection", 
      "world", 
      "prevalence", 
      "Socioeconomic Factor", 
      "old individual", 
      "chronic gastritis", 
      "infected patient", 
      "relevant disease", 
      "atrophic gastritis", 
      "peptic ulcer disease", 
      "public health standpoint", 
      "high impact", 
      "significant morbidity", 
      "mortality", 
      "clinical guideline", 
      "state", 
      "implementation", 
      "recommendation", 
      "high cost", 
      "infection", 
      "health system", 
      "systematic assessment", 
      "treatment strategy", 
      "diagnostic method", 
      "efficient drug", 
      "diagnosis", 
      "management strategy", 
      "infected adult", 
      "outpatient", 
      "Europe", 
      "method", 
      "H. pylorus eradication", 
      "complication", 
      "incidence", 
      "patient", 
      "dyspepsia", 
      "cost-effective strategy", 
      "clinical manifestation", 
      "major health problem", 
      "adult population", 
      "burden", 
      "morbidity", 
      "Residence Characteristic", 
      "symptom", 
      "Referral and Consultation", 
      "gastroenterology", 
      "Treat", 
      "Stomach Ulcer", 
      "evidence", 
      "nature", 
      "chronic inflammatory process", 
      "critical importance", 
      "gastric carcinogenesis", 
      "adenocarcinoma", 
      "mucosa-associated lymphoid tissue", 
      "international agency", 
      "Group 1", 
      "carcinogen", 
      "scientific evidence", 
      "eradication", 
      "cancer prevention", 
      "treatment regimen", 
      "overtime", 
      "monotherapy", 
      "consensus conference", 
      "antibiotic", 
      "clarithromycin", 
      "amoxicillin", 
      "Metronidazole", 
      "proton inhibitor", 
      "Proton Pump Inhibitor", 
      "quadruple", 
      "tetracycline", 
      "bismuth", 
      "levofloxacin", 
      "variant", 
      "induction phase", 
      "second phase", 
      "president", 
      "Francis", 
      "OS", 
      "list", 
      "European country", 
      "research publication", 
      "Research", 
      "committee", 
      "registry", 
      "Fee and Charge", 
      "promoter", 
      "recruiting", 
      "acceptance", 
      "Ambulatory Care Facility", 
      "routine basis", 
      "study variable", 
      "patient identifier", 
      "Gender Identity", 
      "date", 
      "ethnic background", 
      "drug hypersensitivity", 
      "comorbidity", 
      "concomitant medication", 
      "indication", 
      "upper gastrointestinal tract", 
      "current treatment", 
      "prescribed treatment", 
      "dosage", 
      "intake", 
      "treatment compliance", 
      "adherence", 
      "yes/no", 
      "adverse event", 
      "intensity", 
      "duration", 
      "relation", 
      "withdrawal"
    ], 
    "name": "European Registry on the Management of Helicobacter Pylori Infection", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT02328131"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00018.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.5645.2", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.10939.32", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.5807.a", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.45083.3a", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.5808.5", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.410567.1", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.411045.5", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.412354.5", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.10420.37", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.21200.31", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.413305.0", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.412081.e", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.413871.8", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.414852.e", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.410563.5", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.414263.6", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.414037.5", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.4491.8", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.418577.8", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.411251.2", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.416055.3", 
        "type": "Organization"
      }
    ], 
    "startDate": "2013-06-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1111/j.1523-5378.2008.00571.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000637186"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mcg.0b013e31820ac05e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006938735"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(11)60825-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008202000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/gut.2009.192757", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011171868"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmcp1001110", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012270762"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1523-5378.2009.00703.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016295531"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00042737-200501000-00018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017060061"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/meg.0b013e3283069db0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018241444"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bpg.2006.11.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021928527"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2036.2003.01396.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021955673"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1155/2003/714124", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022562812"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2036.2011.04770.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023481821"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.gie.2007.07.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026554414"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mcg.0b013e3181c8a1a3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027708606"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/14651858.cd004062.pub2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027839025"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1053/j.gastro.2008.01.071", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029001608"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2036.2011.04887.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034633045"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ajg.2008.87", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037080330", 
          "https://doi.org/10.1038/ajg.2008.87"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/j.1572-0241.2003.08724.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037375744", 
          "https://doi.org/10.1111/j.1572-0241.2003.08724.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1523-5378.2010.00779.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039764315"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/gutjnl-2012-302084", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040656516"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1523-5378.2011.00829.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041831358"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1523-5378.2007.00485.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045481613"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2036.2012.05211.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049925497"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT02328131"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02328131'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02328131'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02328131'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02328131'


 

This table displays all metadata directly associated to this object as RDF triples.

308 TRIPLES      16 PREDICATES      230 URIs      178 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT02328131 schema:about anzsrc-for:3053
2 anzsrc-for:3114
3 anzsrc-for:3177
4 schema:description The great diversity of regimens and treatment lines, the different efficacy of these, mostly due to the increase in bacterial antibiotic resistance and regional differences, requires a continuous critical analysis of clinical practice, evaluating systematically the efficacy and safety of the different regimens and the cost-effectiveness of the different diagnostic-therapeutic strategies. This will help in the design of an efficient and optimized treatment that will reduce number of re-treatments, diagnostic tests and the appearance of associated pathologies such as peptic ulcers, gastrointestinal bleeding and, probably, gastric cancers. Therefore, the evaluation of real clinical practice using non-interventionist registries will help to improve the design and organization of European Consensus on the management of H. pylori infection, which is the best way to establish healthcare efficiency. Primary aim To obtain a database registering systematically over a year a large and representative sample of routine clinical practice of European gastroenterologists in order to produce descriptive studies of the management of H. pylori infection. Secondary aims 1. To evaluate H. pylori infection consensus and clinical guidelines implementation in different countries. 2. To perform studies focused on epidemiology, efficacy and safety of the commonly used treatments to eradicate H. pylori. 3. To evaluate accessibility to healthcare technologies and drugs used in the management of H. pylori infection. 4. To allow the development of partial and specific analysis by the participating researchers after approval by the Registry's Scientific Committee Methodology Non-interventionist prospective multicentre international registry promoted by the European Helicobacter Study Group. A renowned gastroenterologist from each country was selected as Local Coordinator (30 countries). They will in turn select up to ten gastroenterologists per country that will register the routine clinical practice consultations they receive over 10 years in an electronic Case Report Form (e-CRF). Variables retrieved will include clinical, diagnostic, treatment, eradication confirmation and outcome data. The database will allow researchers to perform specific subanalysis after approval by the Scientific Committee of the study. Detailed Description Abstract Introduction: H. pylori selectively infects the human stomach mucosa, being the most prevalent chronic infection in the world. Its prevalence correlates with socioeconomic factors and it is higher in older individuals. H. pylori presence causes chronic gastritis in 100% of infected patients and is the major cause of relevant diseases such as atrophic gastritis, peptic ulcer disease and gastric cancer; it is for this reason that from a public health standpoint it is considered a high impact pathogen, responsible of a significant morbidity and mortality. Nowadays there are Consensus and Clinical Guidelines regarding the infection management at a European level and in most of the states, but no data have shown the level of implementation of these recommendations. The high costs that this infection carries both socially and to the health system require the continuous and systematic assessment of the diagnostic and treatment strategies, as well as the accessibility to diagnostic methods and most efficient drugs. Aim: To register the treatment, diagnosis and management strategies of H. pylori infected adult patients in the Digestive Services outpatient clinics throughout Europe. Methods: Non-interventionist prospective multicentre international registry promoted by the European Helicobacter Study Group. A renowned gastroenterologist from each country was selected as Local Coordinator (30 countries). They will in turn select up to ten gastroenterologists per country that will register the routine clinical practice consultations they receive over 10 years in an electronic Case Report Form (e-CRF). Variables retrieved will include clinical, diagnostic, treatment, eradication confirmation and outcome data. The database will allow researchers to perform specific subanalysis after approval by the Scientific Committee of the study. INTRODUCTION H. pylori presence causes chronic gastritis in 100% of infected patients and is the major cause of relevant diseases such as atrophic gastritis, peptic ulcer disease and gastric cancer. H. pylori eradication prevents peptic ulcer recurrence and its complications, and decreases the incidence of gastric cancer. H. pylori eradication in patients with peptic ulcer or even functional or non-investigated dyspepsia is a cost-effective strategy. The most common clinical manifestation of H. pylori infection is dyspepsia, a major health problem, whose prevalence reaches more than 10% among adult populations with its attendant burden of morbidity and health system costs in diagnosis and treatment. Approximately 20% to 30% of people in the community each year report chronic or recurrent dyspeptic symptoms, and consultations for dyspepsia account for up to 40% of referrals among gastroenterology outpatients, the "test-and-treat" strategy being the most cost-effective. Moreover, H. pylori is the major cause of peptic ulcer disease, causing over 90% of duodenal and 70% of gastric ulcers. Considerable evidence supports that the nature of the chronic inflammatory process driven by H. pylori is of critical importance in gastric carcinogenesis (adenocarcinoma and mucosa-associated lymphoid tissue -MALT- lymphoma). It is for that reason that the WHO's International Agency for Research on Cancer classified H. pylori as a group 1 (definite) carcinogen. Scientific evidence demonstrates that diagnosis and eradication of H. pylori is the most cost-effective strategy in the management of dyspepsia, peptic ulcer and gastric cancer prevention. The treatment regimens are very diverse and have changed overtime. Monotherapies and treatments with two drugs did not achieve acceptable eradication rates. The commonly recommended regimen in most Consensus Conferences is the standard triple regimen, combining two antibiotics (clarithromycin with amoxicillin or metronidazole) and a proton pump inhibitor (PPI) for 7 to 14 days. Another recommended alternative is bismuth-containing quadruple therapy (PPI, tetracycline, metronidazole and bismuth salts). In the last years, results with new and efficient rescue regimens including levofloxacin have been published. Lately, new treatments have been proposed, including non-bismuth quadruple regimens, with two main variants: the "sequential" treatment (an induction phase with PPI and amoxicillin and a second phase with PPI, clarithromycin and metronidazole) and the "concomitant" treatment (same four drugs taken altogether). The great diversity of regimens and treatment lines, the different efficacy of these, mostly due to the increase in bacterial antibiotic resistance and regional differences, requires a continuous critical analysis of clinical practice, evaluating systematically the efficacy and safety of the different regimens and the cost-effectiveness of the different diagnostic-therapeutic strategies. This will help in the design of an efficient and optimized treatment that will reduce number of re-treatments, diagnostic tests and the appearance of associated pathologies such as peptic ulcers, gastrointestinal bleeding and, probably, gastric cancers. Therefore, the evaluation of real clinical practice using non-interventionist registries will help to improve the design and organization of European Consensus on the management of H. pylori infection, which is the best way to establish healthcare efficiency. AIMS Primary aim To obtain a database registering systematically over a year a large and representative sample of routine clinical practice of European gastroenterologists in order to produce descriptive studies of the management of H. pylori infection. Secondary aims 1. To evaluate H. pylori infection consensus and clinical guidelines implementation in different countries. 2. To perform studies focused on epidemiology, efficacy and safety of the commonly used treatments to eradicate H. pylori. 3. To evaluate accessibility to healthcare technologies and drugs used in the management of H. pylori infection. 4. To allow the development of partial and specific analysis by the participating researchers after approval by the Registry's Scientific Committee. METHODS International multicenter prospective non-interventionist registry promoted by the European Helicobacter Study Group. Scientific Committee - Javier P. Gisbert (President) - Francis Megraud - Colm O'Morain - Adrian G. McNicholl Local Coordinators A list of European Countries has been selected. Included countries were those having at least ten clinical research publications in PubMed regarding H. pylori infection. In each country a Local Coordinator was selected based on its clinical and research activity (Table I). The Local Coordinators will constitute the monitoring and drafting committee of the registry. The Local Coordinators will be in charge of selecting up to 10 recruiting investigators in each country and will be in charge of the follow up and quality of the recruiting; they will be the link between promoters and recruiting investigators. Recruiter Investigators The Recruiting Investigators must be gastroenterologists attending an adult population with a gastroenterology outpatient clinic that assists H. pylori infected patients. Before acceptance the outpatient clinic must attend, in a clinical routine basis, patients in which H. pylori diagnosis or treatment is indicated. Eradication confirmation tests have to be performed routinely. They will register the study variables of their own routine clinical practice in an e-CRF. Study Variables Anonymised Patient Identifiers - Country/Centre/Investigator - Autonumeric Patient identifier number - Gender - Date of Birth - Ethnic Background History and Comorbidity - Drug allergies - Relevant comorbidities - Current concomitant medication Data on Infection - Indication for diagnosis and treatment - Upper Gastrointestinal tract symptoms - Diagnostic Test for current treatment - Number and type of previous eradication attempts Prescribed Treatment - Drugs - Dosage and intakes per day - Length of treatment Compliance - Adherence to treatment (yes/no >90%) Adverse Events - Type of event, intensity, duration and relation with treatment - Treatment withdrawal due to adverse events. Efficacy - Eradication (yes/no), test used, and date
5 schema:endDate 2024-12-01T00:00:00Z
6 schema:keywords Ambulatory Care Facility
7 Bacterial Drug Resistance
8 Case Report
9 DESCRIPTION Abstract
10 Europe
11 European country
12 Evaluation Study as Topic
13 Fee and Charge
14 Francis
15 Gender Identity
16 Group 1
17 H. pylorus
18 H. pylorus eradication
19 H. pylorus infection
20 Helicobacter
21 International
22 Metronidazole
23 OS
24 Proton Pump Inhibitor
25 Referral and Consultation
26 Research
27 Residence Characteristic
28 Routine Diagnostic Test
29 Socioeconomic Factor
30 Stomach Neoplasm
31 Stomach Ulcer
32 Treat
33 acceptance
34 accessibility
35 adenocarcinoma
36 adherence
37 adult population
38 adverse event
39 amoxicillin
40 antibiotic
41 appearance
42 approval
43 associated pathology
44 atrophic gastritis
45 bismuth
46 burden
47 cancer prevention
48 carcinogen
49 chronic gastritis
50 chronic infection
51 chronic inflammatory process
52 clarithromycin
53 clinical guideline
54 clinical manifestation
55 clinical practice
56 committee
57 comorbidity
58 complication
59 concomitant medication
60 confirmation
61 consensus
62 consensus conference
63 coordinator
64 cost-effective strategy
65 cost-effectiveness
66 country
67 critical analysis
68 critical importance
69 current treatment
70 database
71 date
72 descriptive study
73 development
74 diagnosis
75 diagnostic method
76 different country
77 different efficacy
78 different regimen
79 dosage
80 drug
81 drug hypersensitivity
82 duration
83 dyspepsia
84 efficacy
85 efficiency
86 efficient drug
87 epidemiology
88 eradication
89 ethnic background
90 evidence
91 gastric carcinogenesis
92 gastroenterologist
93 gastroenterology
94 great diversity
95 guideline implementation
96 health system
97 healthcare technology
98 high cost
99 high impact
100 human stomach
101 implementation
102 incidence
103 indication
104 induction phase
105 infected adult
106 infected patient
107 infection
108 intake
109 intensity
110 international agency
111 interventionists
112 levofloxacin
113 list
114 major health problem
115 management
116 management strategy
117 method
118 monotherapy
119 morbidity
120 mortality
121 mucosa-associated lymphoid tissue
122 nature
123 old individual
124 outcome data
125 outpatient
126 overtime
127 patient
128 patient identifier
129 peptic ulcer
130 peptic ulcer disease
131 prescribed treatment
132 president
133 prevalence
134 primary aim
135 promoter
136 proton inhibitor
137 public health standpoint
138 quadruple
139 re
140 recommendation
141 recruiting
142 regimen
143 regional difference
144 registering
145 registry
146 relation
147 relevant disease
148 representative sample
149 research publication
150 routine basis
151 routine clinical practice
152 safety
153 scientific committee
154 scientific evidence
155 second phase
156 significant morbidity
157 specific analysis
158 state
159 study group
160 study variable
161 symptom
162 systematic assessment
163 tetracycline
164 therapeutic strategy
165 treatment compliance
166 treatment regimen
167 treatment strategy
168 upper gastrointestinal tract
169 used treatment
170 variable
171 variant
172 withdrawal
173 world
174 yes/no
175 schema:name European Registry on the Management of Helicobacter Pylori Infection
176 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02328131
177 schema:sdDatePublished 2019-03-07T15:25
178 schema:sdLicense https://scigraph.springernature.com/explorer/license/
179 schema:sdPublisher Ne611472d651d4bdab1bfd648337d2c28
180 schema:sponsor https://www.grid.ac/institutes/grid.10420.37
181 https://www.grid.ac/institutes/grid.10939.32
182 https://www.grid.ac/institutes/grid.21200.31
183 https://www.grid.ac/institutes/grid.410563.5
184 https://www.grid.ac/institutes/grid.410567.1
185 https://www.grid.ac/institutes/grid.411045.5
186 https://www.grid.ac/institutes/grid.411251.2
187 https://www.grid.ac/institutes/grid.412081.e
188 https://www.grid.ac/institutes/grid.412354.5
189 https://www.grid.ac/institutes/grid.413305.0
190 https://www.grid.ac/institutes/grid.413871.8
191 https://www.grid.ac/institutes/grid.414037.5
192 https://www.grid.ac/institutes/grid.414263.6
193 https://www.grid.ac/institutes/grid.414852.e
194 https://www.grid.ac/institutes/grid.416055.3
195 https://www.grid.ac/institutes/grid.418577.8
196 https://www.grid.ac/institutes/grid.4491.8
197 https://www.grid.ac/institutes/grid.45083.3a
198 https://www.grid.ac/institutes/grid.5645.2
199 https://www.grid.ac/institutes/grid.5807.a
200 https://www.grid.ac/institutes/grid.5808.5
201 schema:startDate 2013-06-01T00:00:00Z
202 schema:subjectOf sg:pub.10.1038/ajg.2008.87
203 sg:pub.10.1111/j.1572-0241.2003.08724.x
204 https://doi.org/10.1002/14651858.cd004062.pub2
205 https://doi.org/10.1016/j.bpg.2006.11.004
206 https://doi.org/10.1016/j.gie.2007.07.007
207 https://doi.org/10.1016/s0140-6736(11)60825-8
208 https://doi.org/10.1046/j.1365-2036.2003.01396.x
209 https://doi.org/10.1053/j.gastro.2008.01.071
210 https://doi.org/10.1056/nejmcp1001110
211 https://doi.org/10.1097/00042737-200501000-00018
212 https://doi.org/10.1097/mcg.0b013e3181c8a1a3
213 https://doi.org/10.1097/mcg.0b013e31820ac05e
214 https://doi.org/10.1097/meg.0b013e3283069db0
215 https://doi.org/10.1111/j.1365-2036.2011.04770.x
216 https://doi.org/10.1111/j.1365-2036.2011.04887.x
217 https://doi.org/10.1111/j.1365-2036.2012.05211.x
218 https://doi.org/10.1111/j.1523-5378.2007.00485.x
219 https://doi.org/10.1111/j.1523-5378.2008.00571.x
220 https://doi.org/10.1111/j.1523-5378.2009.00703.x
221 https://doi.org/10.1111/j.1523-5378.2010.00779.x
222 https://doi.org/10.1111/j.1523-5378.2011.00829.x
223 https://doi.org/10.1136/gut.2009.192757
224 https://doi.org/10.1136/gutjnl-2012-302084
225 https://doi.org/10.1155/2003/714124
226 schema:url https://clinicaltrials.gov/show/NCT02328131
227 sgo:license sg:explorer/license/
228 sgo:sdDataset clinical_trials
229 rdf:type schema:MedicalStudy
230 Ne611472d651d4bdab1bfd648337d2c28 schema:name Springer Nature - SN SciGraph project
231 rdf:type schema:Organization
232 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
233 rdf:type schema:DefinedTerm
234 anzsrc-for:3114 schema:inDefinedTermSet anzsrc-for:
235 rdf:type schema:DefinedTerm
236 anzsrc-for:3177 schema:inDefinedTermSet anzsrc-for:
237 rdf:type schema:DefinedTerm
238 sg:pub.10.1038/ajg.2008.87 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037080330
239 https://doi.org/10.1038/ajg.2008.87
240 rdf:type schema:CreativeWork
241 sg:pub.10.1111/j.1572-0241.2003.08724.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1037375744
242 https://doi.org/10.1111/j.1572-0241.2003.08724.x
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1002/14651858.cd004062.pub2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027839025
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1016/j.bpg.2006.11.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021928527
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1016/j.gie.2007.07.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026554414
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1016/s0140-6736(11)60825-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008202000
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1046/j.1365-2036.2003.01396.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1021955673
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1053/j.gastro.2008.01.071 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029001608
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1056/nejmcp1001110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012270762
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1097/00042737-200501000-00018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017060061
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1097/mcg.0b013e3181c8a1a3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027708606
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1097/mcg.0b013e31820ac05e schema:sameAs https://app.dimensions.ai/details/publication/pub.1006938735
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1097/meg.0b013e3283069db0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018241444
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1111/j.1365-2036.2011.04770.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1023481821
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1111/j.1365-2036.2011.04887.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1034633045
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1111/j.1365-2036.2012.05211.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1049925497
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1111/j.1523-5378.2007.00485.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1045481613
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1111/j.1523-5378.2008.00571.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1000637186
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1111/j.1523-5378.2009.00703.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1016295531
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1111/j.1523-5378.2010.00779.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1039764315
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1111/j.1523-5378.2011.00829.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1041831358
281 rdf:type schema:CreativeWork
282 https://doi.org/10.1136/gut.2009.192757 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011171868
283 rdf:type schema:CreativeWork
284 https://doi.org/10.1136/gutjnl-2012-302084 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040656516
285 rdf:type schema:CreativeWork
286 https://doi.org/10.1155/2003/714124 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022562812
287 rdf:type schema:CreativeWork
288 https://www.grid.ac/institutes/grid.10420.37 schema:Organization
289 https://www.grid.ac/institutes/grid.10939.32 schema:Organization
290 https://www.grid.ac/institutes/grid.21200.31 schema:Organization
291 https://www.grid.ac/institutes/grid.410563.5 schema:Organization
292 https://www.grid.ac/institutes/grid.410567.1 schema:Organization
293 https://www.grid.ac/institutes/grid.411045.5 schema:Organization
294 https://www.grid.ac/institutes/grid.411251.2 schema:Organization
295 https://www.grid.ac/institutes/grid.412081.e schema:Organization
296 https://www.grid.ac/institutes/grid.412354.5 schema:Organization
297 https://www.grid.ac/institutes/grid.413305.0 schema:Organization
298 https://www.grid.ac/institutes/grid.413871.8 schema:Organization
299 https://www.grid.ac/institutes/grid.414037.5 schema:Organization
300 https://www.grid.ac/institutes/grid.414263.6 schema:Organization
301 https://www.grid.ac/institutes/grid.414852.e schema:Organization
302 https://www.grid.ac/institutes/grid.416055.3 schema:Organization
303 https://www.grid.ac/institutes/grid.418577.8 schema:Organization
304 https://www.grid.ac/institutes/grid.4491.8 schema:Organization
305 https://www.grid.ac/institutes/grid.45083.3a schema:Organization
306 https://www.grid.ac/institutes/grid.5645.2 schema:Organization
307 https://www.grid.ac/institutes/grid.5807.a schema:Organization
308 https://www.grid.ac/institutes/grid.5808.5 schema:Organization
 




Preview window. Press ESC to close (or click here)


...